tomopenem

Tomopenem (formerly known as CS-023 and RO4908463) is an experimental, parenteral, broad-spectrum carbapenem antibiotic. It was originally discovered by Sankyo (now Daiichi Sankyo) and later co-developed with Roche. As a member of the carbapenem class, tomopenem functions by binding to and inhibiting penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. It was specifically noted for its potent activity against Pseudomonas aeruginosa and its unusual activity among carbapenems against methicillin-resistant Staphylococcus aureus (MRSA). The drug reached Phase II clinical trials for the treatment of complicated skin and skin structure infections (cSSSI) and complicated urinary tract infections (cUTI), but development was discontinued by Roche in 2008.